Acticor Biotech SA
PAR:ALACT
Intrinsic Value
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ALACT.
Fundamental Analysis
Balance Sheet Decomposition
Acticor Biotech SA
| Current Assets | 13m |
| Cash & Short-Term Investments | 8m |
| Receivables | 4.4m |
| Other Current Assets | 656k |
| Non-Current Assets | 1.3m |
| Long-Term Investments | 436k |
| PP&E | 28k |
| Intangibles | 713k |
| Other Non-Current Assets | 86k |
| Current Liabilities | 8.6m |
| Accounts Payable | 5.3m |
| Short-Term Debt | 1.9m |
| Other Current Liabilities | 1.4m |
| Non-Current Liabilities | 5.3m |
| Long-Term Debt | 4.3m |
| Other Non-Current Liabilities | 986k |
Earnings Waterfall
Acticor Biotech SA
|
Revenue
|
0
EUR
|
|
Operating Expenses
|
-16.7m
EUR
|
|
Operating Income
|
-16.7m
EUR
|
|
Other Expenses
|
-2m
EUR
|
|
Net Income
|
-18.6m
EUR
|
Free Cash Flow Analysis
Acticor Biotech SA
ALACT Profitability Score
Profitability Due Diligence
Acticor Biotech SA's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Acticor Biotech SA's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
ALACT Solvency Score
Solvency Due Diligence
Acticor Biotech SA's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Acticor Biotech SA's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALACT Price Targets Summary
Acticor Biotech SA
Shareholder Return
ALACT Price
Acticor Biotech SA
| Average Annual Return | 9.14% |
| Standard Deviation of Annual Returns | 60.66% |
| Max Drawdown | -97% |
| Market Capitalization | 18m EUR |
| Shares Outstanding | 15 755 227 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.
You don't have any saved screeners yet
